Our view of a healthy society

Thema:
Healthy society

Improving the physical and mental health of individuals. That’s our ambition. This requires innovation and a new perspective on health and healthcare. Our living environment plays an important role, because healthier living environments prevent almost a quarter of global diseases.

The Dutch government has drawn up a number of missions for the coming years. The goal is that by 2040, all Dutch people will live in good health at least 5 years longer. There should also be a smaller gap between the health of the lowest and highest economic groups. The ambition is to reduce these health differences by 30%.

5 key points for a healthy society

At TNO, we want to make a demonstrable contribution to these missions. Together with government agencies, knowledge institutes, and companies, we develop technological and social innovations that improve health and professional employability. In this way, we contribute to a healthy, vital, and productive population, lower healthcare costs, and increased economic growth. We focus on 5 key points.

1. Effective prevention and behavioural intervention

We make a demonstrable contribution to maintaining health and halving lifestyle and work-related diseases. By preventing or curing these diseases, we can ensure that many people enjoy a better quality of life and we save a lot of money. We therefore contribute to developing innovations that help patients to change their lifestyle, among other things.

2. Personalised digital and analogue health and lifestyle interventions

We believe that personalised prevention, treatment, and support – both digital and analogue – should be the norm. Because everyone is different. Physically, but also in terms of genetic background, mental health, and social context. That's why we develop customised technological solutions and frameworks. For example, personalised pills. We also focus on models to bring data together into personalised and comprehensible recommendations.

3. Faster, better, and cheaper drug development

We want healthcare to remain affordable for everyone and accessible to all. To this end, the production of drugs must be made faster, better, and cheaper. At TNO, we develop technologies and models for this and make them usable by pharmaceutical and biotechnology companies.

4. A healthy, innovative work environment

We contribute to a healthy work environment with safe-by-design solutions, behavioural interventions, and models showing the effects on health. We also work on innovations to predict and control the indoor climate. One example is sensors that let you know if you’re ingesting dangerous substances. In addition, we work towards an inclusive, sustainable, and flexible labour market. This keeps employees healthy and enables them to work longer.

5. Healthy living environment

The environment in which we grow up, live, work, exercise, sleep, and relax affects our health. The combination of exposure to polluted air and noise pollution, for example, has a major impact on us. At TNO, we work with field labs in which we create a healthy living environment through the monitoring of toxic substances and modelling. We do this, for example, by researching the indoor climate (healthy buildings) and through emission measurements and emission distribution models. But also by monitoring air quality from space, assessing exposure, and explaining the effect of exposure.

This is how we work on a healthy society

13 resultaten, getoond 1 t/m 5

TNO helps accelerate drug development through insight

Informatietype:
Insight
14 November 2022

To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.

TNO proves method for effective pediatric drug development

Informatietype:
Insight
14 November 2022

Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.

Translational models TNO excel in preclinical research

Informatietype:
Insight
13 June 2022
TNO’s animal models for NAFLD/NASH are the most translational to human tissue data in a recent Hepatology article about NAFLD/NASH and cardiovascular disease.

Public Private Partnership Arla Food Ingredients and Danone

Informatietype:
Insight
17 March 2022
TNO Healthy Living, Arla & Danone built an in silico model to identify markers needed to assess safety & efficacy of an immune intervention in infants.

International Women’s Day 2022

Informatietype:
Insight
8 March 2022

Today on International Women’s Day we celebrate the success and achievements of women in science for breaking down barriers and challenging the status quo. Get to know some of TNO’s women contributing to a sustainable society every day.